8-K/A: QT Imaging Completes Business Combination, Files Audited Financials

QT Imaging Holdings, Inc. has filed an amendment to its initial 8-K report, including audited financial statements for 2022 and 2023, and pro forma combined financials following its business combination.

Summary

• QT Imaging Holdings, Inc. filed an amendment to its original 8-K report to include audited financial statements for QT Imaging as of December 31, 2023, and for the fiscal years ended December 31, 2023 and 2022.
• The amendment also includes management's discussion and analysis of financial condition and results of operations for the same periods, as well as unaudited pro forma combined financial information for the company as of and for the year ended December 31, 2023.
• The company completed its business combination on March 4, 2024, becoming a publicly-listed company trading on the Nasdaq under the ticker symbol QTI.
• QT Imaging has incurred net operating losses and negative cash flows since its inception, with an accumulated deficit of $17,770,145 as of December 31, 2023.
• For the year ended December 31, 2023, the company reported a net loss of $6,098,951 and used $2,651,143 in operating activities.
• The company's revenue for 2023 was $40,355, a significant decrease from $708,244 in 2022, primarily due to fewer scanner sales.
• Operating expenses totaled $4,913,326 in 2023, compared to $5,937,613 in 2022, with a decrease in research and development expenses partially offset by an increase in professional services related to the business combination.
• The company has secured additional financing through debt and stock subscription agreements, including a $9,005,000 pre-paid advance from Yorkville and a $1,500,000 note from Funicular Funds, LP.
• The Standby Equity Purchase Agreement with Yorkville provides access to an additional $40 million of potential capital.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the business combination and new financing are positive, the significant revenue decline, continued losses, and accumulated deficit raise concerns. The company's future success is highly dependent on its ability to commercialize its products and achieve profitability.

Positives

• The business combination provides QT Imaging with access to public markets and potential for future capital raises.
• The company has secured significant additional financing through debt and stock subscription agreements.
• The Standby Equity Purchase Agreement with Yorkville provides access to a substantial amount of additional capital.
• Research and development expenses decreased in 2023, indicating potential cost management.
• Selling, general, and administrative expenses also decreased, reflecting a reduction in headcount and cost control measures.

Negatives

• The company has incurred significant net operating losses and negative cash flows since its inception.
• Revenue decreased dramatically in 2023 due to a lack of scanner sales.
• The company has a substantial accumulated deficit of $17,770,145 as of December 31, 2023.
• The company recorded a significant debt extinguishment loss of $376,086 in 2023.
• The company's ability to achieve and sustain profitability is uncertain and dependent on achieving sufficient revenues.

Risks

• The company's ability to achieve and sustain profitability is uncertain and dependent on achieving sufficient revenues.
• The company may need to raise additional capital, and there is no guarantee that it will be able to do so on acceptable terms.
• The company's future capital requirements will depend on various factors, including its growth rate and spending on research and development.
• The company's products require regulatory approvals, and there is a risk that these approvals may be delayed or denied.
• The company relies on a limited number of suppliers, and the loss of any of these suppliers could have a material adverse impact.
• The company is subject to risks associated with operating as a public company, including increased compliance costs.

Future Outlook

The company expects to continue to incur losses and will need to raise additional capital. The company's future capital requirements will depend on many factors, including its growth rate, the timing and extent of its spending to support research and development activities, and the timing and cost to introduce new and enhanced products. Management believes that the additional cash received and financing arrangements at the closing of the Business Combination has alleviated the substantial doubt about the Company's ability to continue as a going concern and will be sufficient to fund the Company's current operating plan for at least the next 12 months from the date of issuance of these consolidated financial statements.

Management Comments

• Management believes that the additional cash received and financing arrangements at the closing of the Business Combination has alleviated the substantial doubt about the Company's ability to continue as a going concern.
• Management believes that the additional cash received and financing arrangements at the closing of the Business Combination will be sufficient to fund the Company's current operating plan for at least the next 12 months from the date of issuance of these consolidated financial statements.

Industry Context

The announcement reflects a trend of medical device companies seeking public funding through business combinations with SPACs. The company's focus on low-energy sound imaging aligns with a growing interest in radiation-free medical imaging technologies. The company's technology is positioned to compete with traditional imaging methods, such as mammography, and other ultrasound technologies.

Comparison to Industry Standards

• The company's revenue of $40,355 in 2023 is significantly lower than established medical device companies, which typically generate millions or billions in annual revenue.
• The company's net loss of $6,098,951 is typical for early-stage medical device companies that are still in the development and commercialization phase.
• The company's reliance on external funding through debt and equity is common for companies in this sector, especially those with high research and development costs.
• The company's technology, based on ultra-low frequency transmitted sound, is a differentiator compared to traditional ultrasound and other imaging modalities.
• The company's focus on breast imaging is a competitive market, with established players like Hologic and GE Healthcare, but the company's technology offers a radiation-free alternative.

Related Party Transactions

• The company issued convertible notes to three of its stockholders for advances up to $3,500,000.
• The company issued a promissory note to a shareholder for a principal amount of $705,000.
• The company has a Management Services Agreement with John C. Klock, M.D., the CEO, who is also a significant shareholder.
• A downpayment of $200,000 was made for a breast imaging system by 303 Development Corporation, whose executive director is a current investor and board member of the Company.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• Employees may be impacted by the company's cost-cutting measures.
• Customers will benefit from the company's innovative imaging technology.
• Suppliers will be impacted by the company's production and sales volumes.
• Creditors will be impacted by the company's debt obligations and ability to repay.

Next Steps

• The company will focus on commercializing its QT Breast Scanner and developing its full-body scanner product candidate.
• The company will need to manage its operating expenses and continue to seek additional funding.
• The company will need to obtain regulatory approvals for its products and expand its sales and marketing capabilities.
• The company will need to meet the requirements of the earnout provisions of the business combination agreement.

Key Dates

Keywords

QT Imaging, business combination, medical imaging, breast scanner, financial statements, pro forma, Nasdaq, debt financing, equity financing, operating loss, revenue, research and development, Yorkville, Funicular Funds, convertible notes